Helen Sabzevari - Jun 24, 2021 Form 4 Insider Report for Kinnate Biopharma Inc. (KNTE)

Role
Director
Signature
/s/ Mark Meltz, attorney-in-fact
Stock symbol
KNTE
Transactions as of
Jun 24, 2021
Transactions value $
$0
Form type
4
Date filed
6/28/2021, 01:04 PM
Previous filing
May 14, 2021
Next filing
Jul 20, 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KNTE Stock Option (right to buy) Award $0 +40.5K $0.00 40.5K Jun 24, 2021 Common Stock 40.5K $24.38 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/36th of the shares underlying the Option vest and become exercisable on each monthly anniversary of the Date of Grant.